Gyeonggi-do, South Korea

Miseon Bae

USPTO Granted Patents = 4 


 

Average Co-Inventor Count = 9.6

ph-index = 2

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 2017-2020

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations of Miseon Bae in Pharmaceutical Development

Introduction

Miseon Bae is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit histone deacetylase 6 (HDAC6). With a total of four patents to his name, Bae's work is paving the way for new therapeutic options.

Latest Patents

Miseon Bae's latest patents include innovative compounds such as 1,3,4-oxadiazole sulfonamide derivative compounds. These compounds are recognized for their HDAC6 inhibitory activity. The inventions also encompass pharmaceutical compositions that utilize these compounds for the treatment of various diseases. The novel compounds are effective in preventing or treating HDAC6-mediated diseases, which include infectious diseases, neoplasms, and neurological disorders, among others.

Career Highlights

Bae is currently associated with Chong Kun Dang Pharmaceutical Corporation, where he continues to advance his research and development efforts. His work is instrumental in creating new therapeutic medicaments that can significantly impact patient care.

Collaborations

Miseon Bae collaborates with talented individuals such as Jaekwang Lee and Yuntae Kim. Their combined expertise enhances the innovative potential of their projects.

Conclusion

Miseon Bae's contributions to pharmaceutical innovations demonstrate his commitment to advancing medical science. His work on HDAC6 inhibitors is particularly promising for the treatment of various diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…